NEW YORK--(BUSINESS WIRE)--LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, announced today that it has initiated coverage of Aradigm Corporation (OTCBB: ARDM), an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation anthrax and tularemia infections and smoking cessation.
